These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Discovery of a Potent and Selective PI3Kδ Inhibitor ( Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity. Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316 [TBL] [Abstract][Full Text] [Related]
8. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor. Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348 [TBL] [Abstract][Full Text] [Related]
9. Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation. Bruno P; Micoli A; Corsi M; Pala D; Guariento S; Fiorelli C; Ronchi P; Fioni A; Gallo PM; Marenghi G; Bertolini S; Capacchi S; Mileo V; Biagetti M; Capelli AM J Med Chem; 2024 Jul; 67(13):11103-11124. PubMed ID: 38907711 [TBL] [Abstract][Full Text] [Related]
10. Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation. Yang C; Xu C; Li Z; Chen Y; Wu T; Hong H; Lu M; Jia Y; Yang Y; Liu X; Deng M; Chen Z; Li Q; Ling Y; Zhou Y Eur J Med Chem; 2021 Nov; 223():113661. PubMed ID: 34237636 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a new series of PI3K-δ inhibitors from Virtual Screening. Fradera X; Deng Q; Achab A; Garcia Y; Kattar SD; McGowan MA; Methot JL; Wilson K; Zhou H; Shaffer L; Goldenblatt P; Tong V; Augustin MA; Altman MD; Lesburg CA; Shah S; Katz JD Bioorg Med Chem Lett; 2021 Jun; 42():128046. PubMed ID: 33865969 [TBL] [Abstract][Full Text] [Related]
12. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors. Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors. Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616 [TBL] [Abstract][Full Text] [Related]
14. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma. Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541 [TBL] [Abstract][Full Text] [Related]
15. Optimization and in vivo evaluation of pyrazolopyridines as a potent and selective PI3Kδ inhibitor. Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Moritomo A; Kubo S; Nakamura K; Yamagami K; Hamakawa N; Yokoo K; Fukahori H Bioorg Med Chem; 2018 Aug; 26(14):3917-3924. PubMed ID: 29907471 [TBL] [Abstract][Full Text] [Related]
16. Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma. Perry MWD; Björhall K; Bold P; Brűlls M; Börjesson U; Carlsson J; Chang HA; Chen Y; Eriksson A; Fihn BM; Fransson R; Fredlund L; Ge H; Huang H; Karabelas K; Lamm Bergström E; Lever S; Lindmark H; Mogemark M; Nikitidis A; Palmgren AP; Pemberton N; Petersen J; Rodrigo Blomqvist M; Smith RW; Thomas MJ; Ullah V; Tyrchan C; Wennberg T; Westin Eriksson A; Yang W; Zhao S; Öster L J Med Chem; 2021 Jun; 64(12):8053-8075. PubMed ID: 34080862 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3Kδ inhibitors. Wang NY; Zuo WQ; Hu R; Wang WL; Zhu YX; Xu Y; Yu LT; Liu ZH Bioorg Med Chem Lett; 2020 Oct; 30(20):127479. PubMed ID: 32784091 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors. Yang X; Deng M; Zhang X; Wang Y; Song K; Cong R; Meng L; Zhang J Chem Biol Drug Des; 2019 Dec; 94(6):2013-2022. PubMed ID: 30381889 [TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis. Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045 [TBL] [Abstract][Full Text] [Related]
20. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors. Ma CC; Zhang CM; Tang LQ; Liu ZP Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]